Does the media refer more to SION or RYTM?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Rhythm Pharmaceuticals' score of 0.34 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SION or MIRM?

In the previous week, Sionna Therapeutics had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 4 mentions for Sionna Therapeutics and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Sionna Therapeutics' score of 0.87 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SION or LNTH?

In the previous week, Lantheus had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Lantheus' score of 0.71 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SION or COGT?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is SION or COGT more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Cogent Biosciences N/A -104.27% -54.64%

Does the media favor SION or COGT?

In the previous week, Sionna Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Sionna Therapeutics and 2 mentions for Cogent Biosciences. Sionna Therapeutics' average media sentiment score of 0.87 beat Cogent Biosciences' score of 0.45 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ERAS or SION?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A

Is ERAS or SION more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Sionna Therapeutics N/A -27.31% -25.88%

Does the media prefer ERAS or SION?

In the previous week, Erasca had 36 more articles in the media than Sionna Therapeutics. MarketBeat recorded 40 mentions for Erasca and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Erasca's score of 0.13 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 3 Positive mention(s) 29 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sionna Therapeutics (SION) Competitors

$46.83 +1.14 (+2.50%)

As of 10:01 AM Eastern

Compare

SION vs. RYTM, MIRM, LNTH, COGT, and ERAS

Should you buy Sionna Therapeutics stock or one of its competitors? MarketBeat compares Sionna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sionna Therapeutics include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Sionna Therapeutics (NASDAQ:SION) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Sionna Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Rhythm Pharmaceuticals	$189.76M	38.20	-$196.54M	-$3.13	N/A

Sionna Therapeutics currently has a consensus price target of $53.22, suggesting a potential upside of 14.10%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 30.73%. Given Rhythm Pharmaceuticals' higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Sionna Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Rhythm Pharmaceuticals' score of 0.34 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sionna Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Sionna Therapeutics' return on equity of -27.31% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Sionna Therapeutics beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Sionna Therapeutics (NASDAQ:SION) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Sionna Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Sionna Therapeutics presently has a consensus price target of $53.22, indicating a potential upside of 14.10%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 22.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Sionna Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

In the previous week, Sionna Therapeutics had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 4 mentions for Sionna Therapeutics and 2 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Sionna Therapeutics' score of 0.87 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Mirum Pharmaceuticals	$521.31M	13.71	-$23.36M	-$13.61	N/A

Summary

Mirum Pharmaceuticals beats Sionna Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Lantheus?

Sionna Therapeutics (NASDAQ:SION) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Lantheus has a net margin of 18.05% compared to Sionna Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Lantheus	18.05%	29.32%	15.00%

In the previous week, Lantheus had 2 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Lantheus' score of 0.71 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sionna Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Sionna Therapeutics presently has a consensus price target of $53.22, indicating a potential upside of 14.10%. Lantheus has a consensus price target of $110.43, indicating a potential upside of 6.09%. Given Sionna Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sionna Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Lantheus	$1.55B	4.38	$233.56M	$4.15	25.08

Summary

Lantheus beats Sionna Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Cogent Biosciences?

Sionna Therapeutics (NASDAQ:SION) and Cogent Biosciences (NASDAQ:COGT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Sionna Therapeutics' return on equity of -27.31% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Cogent Biosciences	N/A	-104.27%	-54.64%

Sionna Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Sionna Therapeutics currently has a consensus target price of $53.22, suggesting a potential upside of 14.10%. Cogent Biosciences has a consensus target price of $45.90, suggesting a potential upside of 18.30%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Sionna Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Sionna Therapeutics and 2 mentions for Cogent Biosciences. Sionna Therapeutics' average media sentiment score of 0.87 beat Cogent Biosciences' score of 0.45 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sionna Therapeutics beats Cogent Biosciences on 8 of the 11 factors compared between the two stocks.

How does Sionna Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Sionna Therapeutics (NASDAQ:SION) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Erasca had 36 more articles in the media than Sionna Therapeutics. MarketBeat recorded 40 mentions for Erasca and 4 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.87 beat Erasca's score of 0.13 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	3 Positive mention(s)	29 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Erasca presently has a consensus target price of $21.64, indicating a potential upside of 12.43%. Sionna Therapeutics has a consensus target price of $53.22, indicating a potential upside of 14.10%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Sionna Therapeutics' return on equity of -27.31% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Erasca has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Summary

Sionna Therapeutics beats Erasca on 8 of the 14 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.11B	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-24.17	20.71	27.09	24.07
Price / Sales	N/A	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	6.78	7.99	10.64	6.20
Net Income	-$75.27M	$23.81M	$3.60B	$331.63M
7 Day Performance	9.96%	-1.92%	-1.41%	-1.54%
1 Month Performance	25.55%	1.88%	0.97%	-1.17%
1 Year Performance	168.52%	43.58%	24.23%	17.81%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	1.9368 of 5 stars	$46.65 +2.1%	$53.22 +14.1%	+172.9%	$2.11B	N/A	N/A	35	News Coverage
RYTM Rhythm Pharmaceuticals	2.9184 of 5 stars	$106.09 -3.3%	$138.29 +30.3%	+17.3%	$7.52B	$189.76M	N/A	140	News Coverage
MIRM Mirum Pharmaceuticals	3.2352 of 5 stars	$117.36 -3.0%	$143.40 +22.2%	+124.6%	$7.38B	$521.31M	N/A	140	Positive News
LNTH Lantheus	2.8788 of 5 stars	$105.11 +0.8%	$110.43 +5.1%	+48.8%	$6.79B	$1.54B	25.33	1,193
COGT Cogent Biosciences	1.9524 of 5 stars	$37.94 -3.5%	$43.73 +15.3%	+206.6%	$6.72B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. RYTM, MIRM, LNTH, COGT, and ERAS

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to Lantheus?

Summary

How does Sionna Therapeutics compare to Cogent Biosciences?

Summary

How does Sionna Therapeutics compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. RYTM, MIRM, LNTH, COGT, and ERAS

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Which has preferable earnings & valuation, SION or RYTM?

Do analysts rate SION or RYTM?

Which has more risk and volatility, SION or RYTM?

Does the media refer more to SION or RYTM?

Is SION or RYTM more profitable?

Summary

How does Sionna Therapeutics compare to Mirum Pharmaceuticals?

Is SION or MIRM more profitable?

Do analysts recommend SION or MIRM?

Which has more volatility and risk, SION or MIRM?

Does the media prefer SION or MIRM?

Which has preferable valuation & earnings, SION or MIRM?

Summary

How does Sionna Therapeutics compare to Lantheus?

Is SION or LNTH more profitable?

Does the media prefer SION or LNTH?

Do insiders and institutionals have more ownership in SION or LNTH?

Which has more risk & volatility, SION or LNTH?

Do analysts prefer SION or LNTH?

Which has stronger valuation & earnings, SION or LNTH?

Summary

How does Sionna Therapeutics compare to Cogent Biosciences?

Is SION or COGT more profitable?

Which has more volatility and risk, SION or COGT?

Do analysts recommend SION or COGT?

Which has better valuation and earnings, SION or COGT?

Does the media favor SION or COGT?

Summary

How does Sionna Therapeutics compare to Erasca?

Does the media prefer ERAS or SION?

Do institutionals and insiders believe in ERAS or SION?

Do analysts recommend ERAS or SION?

Is ERAS or SION more profitable?

Which has more volatility & risk, ERAS or SION?

Which has better valuation and earnings, ERAS or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools